Korn Triyangkulsri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Korn Triyangkulsri has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Suthinee Rutnin
Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
5 shared publications - Poonkiat Suchonwanit
Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Thailand
3 shared publications - Amornrut Namasondhi
Division of Dermatology, Faculty of Medicine Ramathibodi Hospital Mahidol University Bangkok Thailand
1 shared publication Bantita Phruttinarakorn
Department of Pathology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
1 shared publication- Chaninan Kositkuljorn
Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
1 shared publication - Kanchana Leerunyakul
Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
1 shared publication
Latest Publications
- Open Access
- 27 May 2026
- Published by Wolters Kluwer Health in The American Journal of Dermatopathology
Diagnostic and Prognostic Values of PRAME Immunohistochemistry in Acral Lentiginous Melanoma
Background: PReferentially Expressed Antigen in MElanoma (PRAME) was introduced as an ancillary tool for confirming the diagnosis of cutaneous melanoma, including the acral lentiginous melanoma (ALM). However, its standardized cut-off values and prognostic performance remain inconclusive. This study assessed the diagnostic performance of PRAME immunohistochemistry (IHC) in ALM across different thresholds and explored its prognostic associations. Methods: This retrospective cohort study reviewed 90 acral melanocytic lesions, including 60 cases of acral benign nevi and 30 cases of primary ALM. PRAME immunohistochemistry was performed on the biopsy specimens. Sensitivity and specificity were calculated at varying cut-offs. The optimal threshold was applied to link PRAME expression with the outcome and features of ALM. Results: A PRAME staining threshold of 50% (score ≥3) provided the optimum cut-off for differentiating ALM, with a high specificity of 98.3% and sensitivity of 53.3%. Positive PRAME was significantly associated with higher TNM stages (ordinal odds ratio [95% confidence interval], 13.11 [2.55–67.27]) and higher rates of recurrence (hazard ratio, 6.62 [1.42–30.94]) but not with any unfavorable histopathological features or mortality. Conclusion: PRAME can be used as an adjunctive diagnostic tool to differentiate malignant from benign acral melanocytic lesions. It may serve as a prognostic marker for poor ALM outcomes.
- 27 May 2026
- Published by Wolters Kluwer Health in The American Journal of Dermatopathology
Open AccessDiagnostic and Prognostic Values of PRAME Immunohistochemistry in Acral Lentiginous Melanoma
Background: PReferentially Expressed Antigen in MElanoma (PRAME) was introduced as an ancillary tool for confirming the diagnosis of cutaneous melanoma, including the acral lentiginous melanoma (ALM). However, its standardized cut-off values and prognostic performance remain inconclusive. This study assessed the diagnostic performance of PRAME immunohistochemistry (IHC) in ALM across different thresholds and explored its prognostic associations. Methods: This retrospective cohort study reviewed 90 acral melanocytic lesions, including 60 cases of acral benign nevi and 30 cases of primary ALM. PRAME immunohistochemistry was performed on the biopsy specimens. Sensitivity and specificity were calculated at varying cut-offs. The optimal threshold was applied to link PRAME expression with the outcome and features of ALM. Results: A PRAME staining threshold of 50% (score ≥3) provided the optimum cut-off for differentiating ALM, with a high specificity of 98.3% and sensitivity of 53.3%. Positive PRAME was significantly associated with higher TNM stages (ordinal odds ratio [95% confidence interval], 13.11 [2.55–67.27]) and higher rates of recurrence (hazard ratio, 6.62 [1.42–30.94]) but not with any unfavorable histopathological features or mortality. Conclusion: PRAME can be used as an adjunctive diagnostic tool to differentiate malignant from benign acral melanocytic lesions. It may serve as a prognostic marker for poor ALM outcomes.
- Open Access
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1) , 4572946
Clinical and Trichoscopic Differentiation of Fibrosing Alopecia in a Pattern Distribution From Female Pattern Hair Loss: A Biopsy‐Confirmed Diagnostic Accuracy Study
Female pattern hair loss (FPHL) and fibrosing alopecia in a pattern distribution (FAPD) share similar clinical presentations but differ fundamentally in pathophysiology and management. Reliable, noninvasive trichoscopic criteria to distinguish these entities remain inadequately defined. This prospective cross‐sectional study enrolled 63 consecutive women with biopsy‐confirmed patterned alopecia (21 FAPD and 42 FPHL), matched for hair loss severity using the Sinclair scale, to compare clinical and trichoscopic features and develop a hierarchical diagnostic algorithm. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and area under the curve (AUC) were calculated with 95% confidence intervals. Loss of follicular ostia was identified in all FAPD cases, but only 2.4% of FPHL cases (AUC 0.99), and white fibrotic patches occurred exclusively in FAPD (47.6%), while yellow dots were found only in FPHL (83.3%). Vellus hairs > 10% were significantly less frequent in FAPD than FPHL (47.6% vs. 95.2%), reflecting a relative vellus hair depletion, termed the “vellus paradox,” likely caused by preferential destruction of miniaturized follicles by the lichenoid inflammatory process. FAPD patients also had shorter disease duration and more frequent scalp symptoms, including burning sensation and tenderness. A hierarchical two‐step trichoscopic algorithm using specificity‐based rule‐in (loss of follicular ostia or white fibrotic patches) and sensitivity‐based rule‐out heuristics (hair diameter diversity or vellus proportion) achieved 100% sensitivity, 97.6% specificity, and 98.4% overall accuracy (AUC 0.99) for identifying FAPD. Distinct trichoscopic features, particularly loss of follicular ostia, white fibrotic patches, and relative vellus hair depletion, reliably differentiate FAPD from FPHL. The proposed algorithm enables rapid, noninvasive bedside diagnosis in this derivation cohort; external validation is required before routine implementation.
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1) , 4572946
Open AccessClinical and Trichoscopic Differentiation of Fibrosing Alopecia in a Pattern Distribution From Female Pattern Hair Loss: A Biopsy‐Confirmed Diagnostic Accuracy Study
Female pattern hair loss (FPHL) and fibrosing alopecia in a pattern distribution (FAPD) share similar clinical presentations but differ fundamentally in pathophysiology and management. Reliable, noninvasive trichoscopic criteria to distinguish these entities remain inadequately defined. This prospective cross‐sectional study enrolled 63 consecutive women with biopsy‐confirmed patterned alopecia (21 FAPD and 42 FPHL), matched for hair loss severity using the Sinclair scale, to compare clinical and trichoscopic features and develop a hierarchical diagnostic algorithm. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and area under the curve (AUC) were calculated with 95% confidence intervals. Loss of follicular ostia was identified in all FAPD cases, but only 2.4% of FPHL cases (AUC 0.99), and white fibrotic patches occurred exclusively in FAPD (47.6%), while yellow dots were found only in FPHL (83.3%). Vellus hairs > 10% were significantly less frequent in FAPD than FPHL (47.6% vs. 95.2%), reflecting a relative vellus hair depletion, termed the “vellus paradox,” likely caused by preferential destruction of miniaturized follicles by the lichenoid inflammatory process. FAPD patients also had shorter disease duration and more frequent scalp symptoms, including burning sensation and tenderness. A hierarchical two‐step trichoscopic algorithm using specificity‐based rule‐in (loss of follicular ostia or white fibrotic patches) and sensitivity‐based rule‐out heuristics (hair diameter diversity or vellus proportion) achieved 100% sensitivity, 97.6% specificity, and 98.4% overall accuracy (AUC 0.99) for identifying FAPD. Distinct trichoscopic features, particularly loss of follicular ostia, white fibrotic patches, and relative vellus hair depletion, reliably differentiate FAPD from FPHL. The proposed algorithm enables rapid, noninvasive bedside diagnosis in this derivation cohort; external validation is required before routine implementation.
- Open Access
- 1 January 2025
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 18, 177-182
Lymphomatoid Papulosis Type E With T-Cell Receptor Gamma Positivity
Lymphomatoid papulosis (LyP) is currently categorized as a primary lymphoproliferative disorder that follows a chronic, recurrent clinical course. The diagnosis of LyP is mainly based on clinical presentation and histopathological correlation. Six subtypes of LyP have been described and recognized, each with different histological features and sometimes distinct clinical presentations. LyP type E is a subtype that histologically shows angioinvasion and angiodestruction by CD8 and CD30-positive pleomorphic T cells. Clinically, it usually presents with a few large necrotic nodules or ulcers on the trunk or extremities, unlike other subtypes of LyP. Despite an indolent clinical course, long-term follow-up is necessary due to the risk of developing concurrent or secondary lymphoma. In this report, we demonstrate a case of lymphomatoid papulosis type E presented with widespread small papulonecrotic eruptions, an atypical clinical manifestation, and an unusual immunohistochemical profile. The biopsy revealed CD8, CD30, CD56, and TCR-γ-positive atypical lymphocytic infiltration with angioinvasion and angiodestruction. The patient was successfully treated with low-dose methotrexate.
- 1 January 2025
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 18, 177-182
Open AccessLymphomatoid Papulosis Type E With T-Cell Receptor Gamma Positivity
Lymphomatoid papulosis (LyP) is currently categorized as a primary lymphoproliferative disorder that follows a chronic, recurrent clinical course. The diagnosis of LyP is mainly based on clinical presentation and histopathological correlation. Six subtypes of LyP have been described and recognized, each with different histological features and sometimes distinct clinical presentations. LyP type E is a subtype that histologically shows angioinvasion and angiodestruction by CD8 and CD30-positive pleomorphic T cells. Clinically, it usually presents with a few large necrotic nodules or ulcers on the trunk or extremities, unlike other subtypes of LyP. Despite an indolent clinical course, long-term follow-up is necessary due to the risk of developing concurrent or secondary lymphoma. In this report, we demonstrate a case of lymphomatoid papulosis type E presented with widespread small papulonecrotic eruptions, an atypical clinical manifestation, and an unusual immunohistochemical profile. The biopsy revealed CD8, CD30, CD56, and TCR-γ-positive atypical lymphocytic infiltration with angioinvasion and angiodestruction. The patient was successfully treated with low-dose methotrexate.
- Open Access
- 1 December 2024
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 17, 2823-2828
Late-Onset Eruptive Clear Cell Syringoma: A Case Report and Literature Review
Eruptive syringoma, a rare subtype of syringoma, is a benign adnexal tumor arising from the eccrine sweat glands. It is characterized by multiple asymptomatic, flat-topped, brown-pigmented papules. The disease typically occurs during adolescence and young adulthood. The clear cell variant of syringoma, which histologically features ductal epithelial cells with clear cytoplasm, is relatively rare, while eruptive clear cell syringoma is even more infrequent. In this report, we present a case of a 64-year-old Thai woman who developed multiple erythematous to brownish papules on her right cheek, which eventually spread to the periorbital region, face, neck, and chest over five years. The diagnosis of late-onset eruptive clear cell syringoma was made based on the patient's clinical manifestations and confirmed by histopathological examination. Notably, the patient was found to have impaired fasting plasma glucose upon screening, highlighting the potential association between clear cell syringoma and glucose metabolism abnormalities. This case report emphasizes the importance of considering this diagnosis in elderly patients presenting with eruptive papular dermatoses and underscores the need for metabolic screening in affected individuals.
- 1 December 2024
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 17, 2823-2828
Open AccessLate-Onset Eruptive Clear Cell Syringoma: A Case Report and Literature Review
Eruptive syringoma, a rare subtype of syringoma, is a benign adnexal tumor arising from the eccrine sweat glands. It is characterized by multiple asymptomatic, flat-topped, brown-pigmented papules. The disease typically occurs during adolescence and young adulthood. The clear cell variant of syringoma, which histologically features ductal epithelial cells with clear cytoplasm, is relatively rare, while eruptive clear cell syringoma is even more infrequent. In this report, we present a case of a 64-year-old Thai woman who developed multiple erythematous to brownish papules on her right cheek, which eventually spread to the periorbital region, face, neck, and chest over five years. The diagnosis of late-onset eruptive clear cell syringoma was made based on the patient's clinical manifestations and confirmed by histopathological examination. Notably, the patient was found to have impaired fasting plasma glucose upon screening, highlighting the potential association between clear cell syringoma and glucose metabolism abnormalities. This case report emphasizes the importance of considering this diagnosis in elderly patients presenting with eruptive papular dermatoses and underscores the need for metabolic screening in affected individuals.
- Open Access
- 24 July 2024
- Published by Elsevier in JAAD Case Reports
- Vol. 52, 94-97
Hemosiderotic diffuse normolipemic plane xanthoma presented with skin hyperpigmentation
- 24 July 2024
- Published by Elsevier in JAAD Case Reports
- Vol. 52, 94-97
Open AccessHemosiderotic diffuse normolipemic plane xanthoma presented with skin hyperpigmentation
- Open Access
- 1 September 2023
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 16, 2497-2502
Two Case Reports of Elastolytic Giant Cell Granuloma on the Palms
Elastolytic giant cell granuloma (EGCG) is a rare granulomatous reaction hypothesized to occur because of the altered antigenicity of elastic fibers, resulting in cellular immunological reactions. The hallmarks of EGCG include elastolysis, elastophagocytosis, and multinucleated giant cell infiltrations. EGCG was first described as an actinic granuloma or annular elastolytic giant cell granuloma that classically presents as centrifugally expanding annular plaques on sun-exposed areas. It was recently named EGCG due to reports of non-annular lesions in various sun-protected areas. Hand involvement has been described but is almost exclusively confined to the dorsal and lateral aspects of the hands. Herein, we report two cases of EGCG on the palms, an unusual site of presentation, that were successfully treated with topical, high-potency corticosteroids. EGCG should be included in the differential diagnosis in cases of annular skin lesions located on the marginal area of the palms.
- 1 September 2023
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 16, 2497-2502
Open AccessTwo Case Reports of Elastolytic Giant Cell Granuloma on the Palms
Elastolytic giant cell granuloma (EGCG) is a rare granulomatous reaction hypothesized to occur because of the altered antigenicity of elastic fibers, resulting in cellular immunological reactions. The hallmarks of EGCG include elastolysis, elastophagocytosis, and multinucleated giant cell infiltrations. EGCG was first described as an actinic granuloma or annular elastolytic giant cell granuloma that classically presents as centrifugally expanding annular plaques on sun-exposed areas. It was recently named EGCG due to reports of non-annular lesions in various sun-protected areas. Hand involvement has been described but is almost exclusively confined to the dorsal and lateral aspects of the hands. Herein, we report two cases of EGCG on the palms, an unusual site of presentation, that were successfully treated with topical, high-potency corticosteroids. EGCG should be included in the differential diagnosis in cases of annular skin lesions located on the marginal area of the palms.
- 24 October 2019
- Published by Springer Nature in Lasers in Medical Science
- Vol. 35 (3) , 695-700
Comparison of fractional neodymium-doped yttrium aluminum garnet (Nd:YAG) 1064-nm picosecond laser and fractional 1550-nm erbium fiber laser in facial acne scar treatment
To compare the safety and efficacy of fractional neodymium-doped yttrium aluminum garnet (Nd:YAG) 1064-nm picosecond laser and fractional 1550-nm erbium fiber laser in acne scar treatment and to assess the adverse effects and complications of the two devices. Thirty patients with cosmetically similar acne scars on both sides of the faces were enrolled and treated four times at 4-week intervals. Each side of the face was treated with either fractional 1064-nm Nd:YAG picosecond laser or fractional 1550-nm erbium fiber laser. Efficacy was evaluated using digital photography taken at baseline and 5 months by a blinded dermatologist using the ECCA grading scale (échelle d’évaluation clinique des cicatrices d’acné). Patient overall satisfaction and self-rated improvement scores were recorded at baseline and 5 months. Adverse effects were recorded at every visit. Twenty-seven patients completed the study. Both devices demonstrated significant median ECCA score improvement from baseline (P < 0.001). However, there was no significant difference between the two in terms of median ECCA score improvement, patients’ perception of scar improvement, and overall satisfaction. Considering the adverse effects, more pinpoint bleeding was significantly observed with the picosecond laser (P = 0.002), whereas more pain was noted with the erbium laser (P < 0.001). Both fractional 1064-nm Nd:YAG picosecond laser and fractional 1550-nm erbium fiber laser are safe and effective in the treatment of acne scars. Costs should be taken into consideration when deciding on which device to use to maximize treatment outcomes.
- 24 October 2019
- Published by Springer Nature in Lasers in Medical Science
- Vol. 35 (3) , 695-700
Comparison of fractional neodymium-doped yttrium aluminum garnet (Nd:YAG) 1064-nm picosecond laser and fractional 1550-nm erbium fiber laser in facial acne scar treatment
To compare the safety and efficacy of fractional neodymium-doped yttrium aluminum garnet (Nd:YAG) 1064-nm picosecond laser and fractional 1550-nm erbium fiber laser in acne scar treatment and to assess the adverse effects and complications of the two devices. Thirty patients with cosmetically similar acne scars on both sides of the faces were enrolled and treated four times at 4-week intervals. Each side of the face was treated with either fractional 1064-nm Nd:YAG picosecond laser or fractional 1550-nm erbium fiber laser. Efficacy was evaluated using digital photography taken at baseline and 5 months by a blinded dermatologist using the ECCA grading scale (échelle d’évaluation clinique des cicatrices d’acné). Patient overall satisfaction and self-rated improvement scores were recorded at baseline and 5 months. Adverse effects were recorded at every visit. Twenty-seven patients completed the study. Both devices demonstrated significant median ECCA score improvement from baseline (P < 0.001). However, there was no significant difference between the two in terms of median ECCA score improvement, patients’ perception of scar improvement, and overall satisfaction. Considering the adverse effects, more pinpoint bleeding was significantly observed with the picosecond laser (P = 0.002), whereas more pain was noted with the erbium laser (P < 0.001). Both fractional 1064-nm Nd:YAG picosecond laser and fractional 1550-nm erbium fiber laser are safe and effective in the treatment of acne scars. Costs should be taken into consideration when deciding on which device to use to maximize treatment outcomes.
- Open Access
- 1 July 2018
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 12, 2323-2335
Role of janus kinase inhibitors in the treatment of alopecia areata
Alopecia areata (AA) is a common hair loss disorder worldwide with characteristic exclamation mark hairs. Although AA is self-limited, it can last for several months or even years in some patients. Currently, there is no US Food and Drug Administration-approved treatment for AA. Many off-label treatments are available but with limited efficacy. Through a better understanding of molecular biology, many targeted therapies have emerged as new alternatives for various autoimmune diseases. Various janus kinase (JAK) and signal transducer and activator of transcription (STAT) proteins form signaling pathways, which transmit extracellular cytokine signals to the nucleus and induce DNA transcriptions. By inhibiting JAK, T-cell-mediated inflammatory responses are suppressed. Increasing evidence suggests that JAK inhibitors (JAKis) are effective in the treatment of many autoimmune diseases, including AA. Among these, several studies on tofacitinib, ruxolitinib, and baricitinib in AA had been published, demonstrating promising outcomes of these agents. Unlike oral formulations, efficacy of topical forms of tofacitinib and ruxolitinib reported in these studies is still unsatisfactory and requires improvement. This review aims to summarize evidence of the efficacy and safety of JAKis in the treatment of AA.
- 1 July 2018
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 12, 2323-2335
Open AccessRole of janus kinase inhibitors in the treatment of alopecia areata
Alopecia areata (AA) is a common hair loss disorder worldwide with characteristic exclamation mark hairs. Although AA is self-limited, it can last for several months or even years in some patients. Currently, there is no US Food and Drug Administration-approved treatment for AA. Many off-label treatments are available but with limited efficacy. Through a better understanding of molecular biology, many targeted therapies have emerged as new alternatives for various autoimmune diseases. Various janus kinase (JAK) and signal transducer and activator of transcription (STAT) proteins form signaling pathways, which transmit extracellular cytokine signals to the nucleus and induce DNA transcriptions. By inhibiting JAK, T-cell-mediated inflammatory responses are suppressed. Increasing evidence suggests that JAK inhibitors (JAKis) are effective in the treatment of many autoimmune diseases, including AA. Among these, several studies on tofacitinib, ruxolitinib, and baricitinib in AA had been published, demonstrating promising outcomes of these agents. Unlike oral formulations, efficacy of topical forms of tofacitinib and ruxolitinib reported in these studies is still unsatisfactory and requires improvement. This review aims to summarize evidence of the efficacy and safety of JAKis in the treatment of AA.